Ratings Ramkhamhaeng Hospital

Equities

End-of-day quote Thailand S.E. Other stock markets 06:00:00 2024-05-12 pm EDT			5-day change	1st Jan Change
30.5 ^THB	-0.81%		-2.40%	-15.28%

Apr. 30	Ramkhamhaeng Hospital Public Company Limited Elects Benny Lim as Director	CI
Mar. 21	Ramkhamhaeng Hospital Public Company Limited Announces Executive Changes	CI

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company benefits from high valuations in earnings multiples.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

	1st Jan change	Capi.	ESG Refinitiv
RAMKHAMHAENG HOSPITAL	-15.28%	995M	-
HCA HEALTHCARE, INC.	+17.18%	83.07B	C+
CVS HEALTH CORPORATION	-28.48%	70.89B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+5.14%	28.32B	C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-7.44%	17.73B	B
FRESENIUS SE & CO. KGAA	+2.28%	17.43B	A-
QUEST DIAGNOSTICS INCORPORATED	+2.10%	15.64B	A-
REDE D'OR SÃO LUIZ S.A.	+7.02%	13.46B	B-
NATERA, INC.	+64.96%	12.69B	C-
FRESENIUS MEDICAL CARE AG	+6.22%	12.82B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality